Dividend investing aims to find companies that provide good yields and have the financial stability to maintain and increase their payouts. The "Best Dividend" screen selects stocks with a high ChartMill Dividend Rating (≥7), indicating strong dividend traits, along with a minimum ChartMill Profitability Rating (≥5) and Health Rating (≥5) to ensure business stability. This method balances income with fundamental strength, lowering the chance of dividend cuts or unsustainable payments.
A stock that fits these requirements is NOVARTIS AG-SPONSORED ADR (NYSE:NVS), a top global pharmaceutical company known for its healthcare advancements and generic drugs.
Why Novartis Appeals to Dividend Investors
1. Attractive Dividend Features
Novartis provides a 3.55% dividend yield, higher than the S&P 500 average (2.36%) and competitive in its sector (average 4.04%). Key points of its dividend appeal include:
- Consistent Payment History: The company has paid dividends for at least 10 years without cuts in the last five years, showing shareholder commitment.
- Manageable Payout Ratio: At 57.26% of earnings, the dividend is sustainable, allowing for reinvestment and future increases.
- Steady Growth: The dividend has grown at an annual rate of 5.49%, matching earnings growth, which supports long-term stability.
These factors match the screening criteria, as a high Dividend Rating reflects not only yield but also reliability and safety, important for income-focused investors.
2. Profitability Ensures Dividend Stability
Novartis has a ChartMill Profitability Rating of 9/10, highlighting strong margins and returns:
- Healthy Margins: Gross margin (76.12%), operating margin (33.45%), and net margin (24.90%) all rank in the top 15% of pharmaceutical peers.
- Effective Capital Use: Return on invested capital (ROIC) of 22.91% is well above its cost of capital, showing efficient value creation.
- Steady Earnings Growth: EPS grew 22.58% YoY, with a 5-year annual growth rate of 8.14%.
Profitability is crucial for dividend strategies, as it ensures the company can support payouts without harming growth or financial stability.
3. Stable Financial Position
With a ChartMill Health Rating of 7/10, Novartis has a solid balance sheet:
- Controlled Debt: A debt-to-FCF ratio of 1.93 means it could repay all debt in less than two years using free cash flow.
- Low Bankruptcy Risk: An Altman-Z score of 3.90 indicates strong solvency, better than 77% of industry peers.
- Shareholder Benefits: The company has reduced shares outstanding over time, improving per-share metrics.
While liquidity ratios (current/quick ratios below 1) seem low, this is typical in capital-heavy industries and is balanced by strong cash flow.
Valuation and Growth Outlook
Novartis trades at a P/E of 14.04, below both the S&P 500 (26.84) and industry average (21.63), suggesting it may be undervalued. Analysts expect 7.33% annual EPS growth, which, though modest, aligns with its dividend growth path.
Final Thoughts
Novartis offers an above-average yield, sustainable payout ratios, and strong profitability, key traits for dividend investors. Its financial health and industry standing further reduce risks tied to income investing. For those looking for a mix of yield and stability in healthcare, NVS is worth considering.
Find More Dividend Stock Ideas
The Best Dividend Stocks screen lists other high-quality dividend stocks filtered by the same strict criteria.
Disclaimer: This analysis is not investment advice. Always do your own research or consult a financial advisor before making investment decisions.
